AMRI Promotes Susan Collins to Director, Business Development
News Jun 18, 2013
AMRI has announced that Susan Collins has been promoted to Director of Business Development for North American Discovery Services, reporting to Christopher Conway, Vice President, Business Development.
In this new role, Ms. Collins is responsible for leading AMRI’s North American Discovery Business Development team in the promotion of the full spectrum of AMRI’s global drug discovery services.
Bringing 19 years of pharmaceutical industry and leadership experience to this role, Ms. Collins will manage AMRI’s North American discovery business development activities and professionals and spearhead AMRI’s efforts to expand discovery opportunities and business within the sector.
Mr. Conway said, “Susan is a top-performing sales professional with a proven ability to drive territorial revenue growth and increase market penetration through exceptional customer relationship skills. Her track record since joining AMRI and prior leadership experience position her well to be very successful in this expanded role. I would like to take this opportunity to publicly congratulate Susan and wish her well in this new position. I look forward to working with her more closely going forward.”
Before joining AMRI’s discovery team in 2012, Ms. Collins held roles of increasing responsibility in sales and leadership positions at OrganonBioSciences, which was later acquired by Schering-Plough and Merck.
As Region Sales Director, she was responsible for leading award-winning management and representative teams in the promotion of CNS, cardiovascular, anti-infective, anesthesia, pain management and contraceptive products to the medical community across 28 states.
Directing teams of up to 125 employees, Ms. Collins was responsible for generating sales of more than $174 million with a $7.8 million operating budget.
Thomas E. D’Ambra, Ph.D., President and CEO, AMRI, said, “AMRI’s business development professionals are integral in creating and building long-term relationships and partnerships with our many customers. AMRI’s discovery services are complex, cover our global locations and require customization of offerings and solutions for our customers’ specific needs. Susan has demonstrated an innovative and ambitious approach to building business and customer relationships since joining AMRI in 2012. We look forward to working with Susan and her team in building our North American discovery business to the next level of success.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018